On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited.
Many inhibitors of monoamine oxidase, particularly those developed during the past three decades, are often referred to as being "selective" for one or other isoform of the enzyme. However true this may be, selectivity within the EC 1.4.3.4 family does not preclude the possibility of interactions of these drugs with other proteins unrelated to monoamine oxidase. Indeed, evidence exists which either suggests or demonstrates directly that many of these inhibitors do interact with, and affect the behaviour of, other enzymes, receptor systems and uptake pumps, with potentially interesting consequences, desirable or otherwise, for the patient or the pharmacologist. An overview of many such interactions, and speculation upon some of the possible consequences, are provided in this review.
Holt
Andrew
A
ALviva Biopharmaceuticals Inc, 218-111 Research Drive, Saskatoon, Saskatchewan, Canada S7N 3R2. andy.holt@ualberta.ca
Berry
Mark D
MD
Boulton
Alan A
AA
D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000378:metabolism*
D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase